Company news
Monopar Therapeutics Inc. news in 2020
Monopar Therapeutics Inc.'s news releases, calls and decks from 2020, newest first.
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
December 21, 2020
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
December 9, 2020
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
December 7, 2020
Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
November 11, 2020
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®
November 8, 2020
Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020
September 13, 2020
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
September 8, 2020
Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
August 18, 2020
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
August 11, 2020
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
August 9, 2020
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
August 5, 2020
Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR
June 29, 2020
Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19
June 15, 2020
Monopar Therapeutics Reports First Quarter 2020 Financial Results and Business Updates
May 6, 2020
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates
March 26, 2020
Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma
February 17, 2020